50606-31-0

Usage

Uses

Used in Pharmaceutical Industry:
METHYL PIPERAZINE-1-CARBOXYLATE is used as a synthetic intermediate for the development of piperazine derivatives. These derivatives act as kinase inhibitors, which play a crucial role in the treatment of diabetes, diabetic complications, and other diseases. The inhibition of specific kinases can help regulate cellular processes and provide therapeutic benefits for patients suffering from these conditions.

InChI:InChI=1/C6H12N2O2/c1-10-6(9)8-4-2-7-3-5-8/h7H,2-5H2,1H3

Upstream product

• 110-85-0 piperazine 
• 17175-16-5 p-nitrophenyl methyl carbonate 
• 219509-79-2 1-(tert-butyl) 4-methyl piperazine-1,4-dicarboxylate 
• 383865-57-4 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine 
• 79-22-1 methyl chloroformate 
• 873697-75-7 methyl piperazine-1,3-carboxylate hydrochloride 

Downstream Products

• 7560-85-2 methyl 4-methylpiperazine-1-carboxylate 
• 873697-63-3 C₁₃H₁₇N₃O₄ 
• 942224-53-5 tert-butyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate 
• 873697-70-2 methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate 
• 873697-81-5 tert-butyl 4-(2-(3-nitrophenyl)acetyl)piperazine-1-carboxylate 
• 873697-72-4 C₁₃H₁₉N₃O₂ 
• 873697-71-3 methyl 4-[(2-fluoro-3-{[(6-methylpyridin-3-yl)carbamoyl]amino}phenyl)methyl]piperazine-1-carboxylate 
• 1309439-45-9 methyl 4-(3-chloro-2-fluorobenzyl)piperazine-1-carboxylate 
• 1391636-60-4 C₁₇H₂₃ClN₂O₄ 
• 1445901-18-7 4-{4-[(N-isobutyl-1-phenylmethylsulfonamino)methyl]phenyl}piperazine-1-carboxylic acid methyl ester 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Disclosed by the invention is a heterocyclic compound, an intermediate, and a preparation method therefor and an application thereof. Provided by the invention are a heterocyclic compound as shown in formula I, and a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof. The heterocyclic compound hasa high P2X3 antagonistic activity, and has good selectivity, low toxicity, good metabolic stability and little taste influence.

ALTERNATE PROCESSES FOR THE PREPARATION OF OMECAMTIV MECARBIL

Aspects of the present application relate to process for the preparation of Omecamtiv mecarbil and salts thereof. Specific aspects relate to novel urea intermediate, preparative process thereof and its use in the preparation of Omecamtiv mecarbil and salts thereof. The improved process for the preparation of Omecamtiv mecarbil are industrially viable.

Development of a Factory Process for Omecamtiv Mecarbil, a Novel Cardiac Myosin Activator

The development of a factory process to manufacture the novel cardiac myosin activator omecamtiv mecarbil (1) is described. Omecamtiv mecarbil is prepared via the convergent synthesis and coupling of two key fragments, aniline 2 and carbamate 4-HCl, which serves as a masked isocyanate. To enable practical access to aniline 2, reduction of the corresponding nitroaromatic was designed to control potential mutagenic impurities. Key to the efficient preparation of 2 was the benzylic bromination of 8 followed by selective debromination of a gem-dibromide byproduct and subsequent alkylation with 5-phosphate. Overall, the longest linear sequence consists of six steps, including a final salt formation step to afford the drug substance in 55% overall yield. Because of poor performance of the original free-base form of the drug substance in modified-release formulations, an improved dihydrochloride hydrate form was developed to aid drug product performance and manufacturability.

Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists

Optimization of a series of aminomethyl ketone diamine H3R antagonists to reduce the brain exposure by lowering the pKa, led to molecules with improved pharmacokinetic properties. Compounds 9, 19, and 25 had high affinity for human H3R and demonstrated in vivo H3R functional activity in the rat dipsogenia model. Compound 9 displayed modest wake-promoting activity in the rat EEG/EMG model.

Unsymmetrical tetrasubstituted ureas from tertiary carbamoylimidazole: Activation by AlMe3

An efficient and general method for the synthesis of unsymmetrical tetrasubstituted ureas from carbamoylimidazole is described. The conversion is achieved by the concurrent quarternization of the imidazole nitrogen and activation of amines with AlMe3. The Royal Society of Chemistry 2012.

Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin

We report the design, synthesis, and optimization of the first, selective activators of cardiac myosin. Starting with a poorly soluble, nitro-aromatic hit compound (1), potent, selective, and soluble myosin activators were designed culminating in the discovery of omecamtiv mecarbil (24). Compound 24 is currently in clinical trials for the treatment of systolic heart failure.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

Benzothiazole derivatives with activity as adenosine receptor ligands

The present invention relates to substituted benzothiazole derivitives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.